Reposted by Andy Hogan
Nanobodies targeting MR1-antigen complexes are engineered to modulate mucosal-associated invariant T cells and target MR1-ligand complexes on tumors
www.science.org/doi/10.1126/... @sciimmunology.bsky.social @thedohertyinst.bsky.social